Methods
MCI, Cancer
CANCER
This study is a non-inferiority RCT conducted at Motamed Cancer Research Institute (MCI) between 2019 and 2023. The primary objective was to examine the effectiveness, benefits, and side effects of a domestically produced medication called Microrelin, available in one-month and three-month formulations by Homa Pharmed pharmaceutical company, and compare them with a similar foreign brand, Diphereline 11.25 mg.